Kvantify

Kvantify launches physics-based 𝙗𝙞𝙣𝙙𝙞𝙣𝙜 𝙖𝙛𝙛𝙞𝙣𝙞𝙩𝙮-software for drug discovery - with high accuracy and unprecedented speed 🔥 We are extremely proud to introduce the next evolution of our computational drug discovery platform. "Currently, benchmark tests show that our binding affinity tool is 100 times faster than comparable state-of-the-art methods with the same level of accuracy. Matching our speed with high accuracy gives us the option to push accurate physics-based binding affinity calculations further up the drug discovery funnel" says Hans Henrik H. Knudsen, CEO of Kvantify With this addition to our platform, we can help our biotech and pharma customers make better decisions - faster. So, if you’re looking for a partner to help guide your drug discovery efforts, reach out! 𝘽𝙞𝙣𝙙𝙞𝙣𝙜 𝘼𝙛𝙛𝙞𝙣𝙞𝙩𝙮 𝙛𝙤𝙧 𝙚𝙫𝙚𝙧𝙮𝙤𝙣𝙚 (learn more) 👉 www.kvantify.com/koffee 𝙋𝙧𝙚𝙨𝙨 𝙍𝙚𝙡𝙚𝙖𝙨𝙚 👉 https://lnkd.in/dkkqGriw 𝘾𝙤𝙣𝙩𝙖𝙘𝙩 📨 contact@kvantify.com

“30 years of facilitating partnerships” 🤝 That’s something to be proud of! At Kvantify we are just getting started, and we are excited to be part of this year’s Bio-Europe conference! We’re looking forward to exciting conversations about drug discovery and the future of biotech. Should we meet up? Stop by our booth #89B or send us a message to arrange a meeting. See you in Stockholm!

A big congratulations to all the partners and to Denmark for joining the supercomputer super league. Well done, Novo Nordisk Foundation, Danmarks Eksport- og Investeringsfond and Danish Centre for AI Innovation (DCAI) 👏 💥Gefion is a NVIDIA DGX SuperPOD AI-supercomputer, driven by 1.528 NVIDIA H100 Tensor Core GPUs 👀

Optimising Compound Screening with Physics-Based Precision. At Kvantify, we understand the challenges biotech and pharma companies face in drug discovery. That’s why we’ve built a cutting-edge computational platform to streamline your compound screening. From early hit identification to lead optimisation, we can help you go from thousands of candidates to just a few high-quality leads - faster than ever. Our high-speed, physics-based algorithms provide the accuracy and reliability you need to push the boundaries of drug discovery. Partner with us and let’s shape the future of therapeutics together!

Maybe you saw us in other media about our physics-based binding affinity tool? In short, we have created a computational method that is approximately 100 times faster than similar products on the market – with comparable accuracy. You can find some of the press pickups here and choose your preferred language: In English: https://lnkd.in/deiHYWGc Auf Deutsch: https://lnkd.in/d9gS68tw En français: https://lnkd.in/dnKwc57J På dansk: https://lnkd.in/d7vCnmSK #Biotech #Pharma #DrugDiscovery #Koffee

At Kvantify, we're pushing the boundaries of computational drug discovery with the latest addition to our Koffee platform: physics-based binding affinity predictions. Our new binding affinity method enhances our offerings, providing a comprehensive suite for small molecule drug discovery. With the ability to rapidly predict how strongly a ligand associates with its target, we are addressing a critical factor in designing effective drugs. Here’s what sets it apart: - Orders of magnitude faster: Our algorithms are optimized for complex calculations, delivering results in minutes instead of hours or days, allowing our partners to navigate drug discovery pipelines with unmatched efficiency. - Precision matching state-of-the-art: Our method is not only fast but also accurate, matching the precision of costlier methods on the market, offering actionable insights earlier. - Physics-based approach: Grounded in physical principles, our calculations yield explainable results that can significantly de-risk the drug discovery process. - Scalable for large libraries: Whether screening hundreds or thousands of compounds, our platform manages the volume effortlessly. Curious about how this could optimise your pipeline? Get in touch. Learn more here: www.kvantify.com/koffee Contact us here: contact@kvantify.com

BioTechX Europe 2024 - we’re here! We’re very excited to be here in Basel to learn and share knowledge with experts in the biotech industry. Our team is onsite ready to talk about how we’re transforming drug discovery with our advanced platform and research partner services. Hans Henrik H. Knudsen is on stage today at the "In Silico R&D" track, presenting the latest developments to our drug discovery platform, Koffee. If you’re here come by our booth #520 near Theatre 10! Learn more about our product 👉 www.kvantify.com/koffee #biotechx #kvantify #drugdiscovery

AI is making waves in drug discovery, but it’s important to recognize the current limitations and challenges. While AI is a powerful tool, it won’t be replacing lab experiments or human expertise anytime soon. Instead, it will enhance how we approach complex problems in drug discovery. At Kvantify, we see the potential of combining AI with physics-based models to overcome obstacles like data sparsity, lack of diversity, and inconsistencies in datasets. Our models provide a rigorous way to validate and complement AI-driven insights, reducing the risks of generalization errors and improving decision-making in drug development. We're proud to offer solutions that help advance drug discovery, especially with our product Koffee that addresses the challenges of predicting unbinding kinetics and binding affinity. Read more in Mikael Hvidtfeldt Christensen blogpost here: https://lnkd.in/dWG8ftSX

Minimising extra swap gates in quantum computing – an optimal and scalable solution. In quantum computing, adding optimal extra swap gates can be costly and complex, particularly when dealing with larger numbers of qubits. While various solutions have been suggested, they often lack two key features: scalability and optimality. A new paper addresses this issue, authored by our quantum research expert Irfansha Shaik, in collaboration with Professor Jaco van de Pol from Aarhus Universitet. Their work introduces a scalable solution to optimal layout synthesis for deep quantum circuits on NISQ processors with 100+ qubits. Irfansha Shaik’s paper was awarded runner-up for Best Student Paper at The International Conference on Theory and Applications of Satisfiability Testing (SAT-2024). As a small spoiler, we can share that Irfansha has already had another paper accepted for the European Conference on Artificial Intelligence, 19-24 October in Santiago de Compostela, Spain (ECAI-2024). Read more about the findings here: https://lnkd.in/dwQ4TuFE And watch the video below to learn more about Irfansha 👇 #QuantumComputing #TechResearch #OptimalSolutions #QuantumInnovation #ScalableTechnology

Thank you to everyone who joined us at the Medicon Valley Alliance Good Morning Meeting last week! We had the pleasure of hosting more attendees than we had imagined, all of whom were eager to dive into the future of drug discovery. It was fantastic to explore how physics-based models and AI are accelerating drug development - reshaping the way we approach complex challenges. A special shoutout to Morten Allesø from Tetra Pharm Technologies for sharing valuable insights about their work in CNS and immune system-targeted therapies. Our collaboration together has opened up new possibilities, and it was great to hear how they are leveraging these novel tools in their research. The event also offered great networking opportunities, where peers exchanged experiences on computational drug discovery (CADD) and discussed emerging trends in pharmaceutical innovation. And remember, you’re always welcome to reach out if you’re curious about what we’re working on!